IL263167B - Antifungal preparation containing 2 (-1,5-dimethyl-3-phenyl-h1-pyrrole-2-yl(- n (-4 (- (-5-fluoropyrimidine- 2-yl(piperazine-1-yl(phenyl) (2-Oxoacetamide for oral administration - Google Patents

Antifungal preparation containing 2 (-1,5-dimethyl-3-phenyl-h1-pyrrole-2-yl(- n (-4 (- (-5-fluoropyrimidine- 2-yl(piperazine-1-yl(phenyl) (2-Oxoacetamide for oral administration

Info

Publication number
IL263167B
IL263167B IL263167A IL26316718A IL263167B IL 263167 B IL263167 B IL 263167B IL 263167 A IL263167 A IL 263167A IL 26316718 A IL26316718 A IL 26316718A IL 263167 B IL263167 B IL 263167B
Authority
IL
Israel
Prior art keywords
formula
compound
pharmaceutical composition
phenyl
pharmaceutically acceptable
Prior art date
Application number
IL263167A
Other languages
English (en)
Hebrew (he)
Other versions
IL263167A (en
Original Assignee
F2G Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F2G Ltd filed Critical F2G Ltd
Publication of IL263167A publication Critical patent/IL263167A/en
Publication of IL263167B publication Critical patent/IL263167B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL263167A 2016-05-25 2017-05-25 Antifungal preparation containing 2 (-1,5-dimethyl-3-phenyl-h1-pyrrole-2-yl(- n (-4 (- (-5-fluoropyrimidine- 2-yl(piperazine-1-yl(phenyl) (2-Oxoacetamide for oral administration IL263167B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609222.3A GB201609222D0 (en) 2016-05-25 2016-05-25 Pharmaceutical formulation
PCT/GB2017/051494 WO2017203270A1 (en) 2016-05-25 2017-05-25 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
IL263167A IL263167A (en) 2018-12-31
IL263167B true IL263167B (en) 2022-07-01

Family

ID=56369959

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263167A IL263167B (en) 2016-05-25 2017-05-25 Antifungal preparation containing 2 (-1,5-dimethyl-3-phenyl-h1-pyrrole-2-yl(- n (-4 (- (-5-fluoropyrimidine- 2-yl(piperazine-1-yl(phenyl) (2-Oxoacetamide for oral administration

Country Status (25)

Country Link
US (2) US10973821B2 (enExample)
EP (1) EP3463365B1 (enExample)
JP (1) JP7141108B2 (enExample)
KR (1) KR102464150B1 (enExample)
CN (1) CN109982704B (enExample)
AU (1) AU2017270942B2 (enExample)
CA (1) CA3024771A1 (enExample)
CY (1) CY1124733T1 (enExample)
DK (1) DK3463365T3 (enExample)
ES (1) ES2888951T3 (enExample)
GB (1) GB201609222D0 (enExample)
HR (1) HRP20211795T1 (enExample)
HU (1) HUE056129T2 (enExample)
IL (1) IL263167B (enExample)
LT (1) LT3463365T (enExample)
MA (1) MA45126A (enExample)
MX (1) MX382199B (enExample)
MY (1) MY197663A (enExample)
PL (1) PL3463365T3 (enExample)
PT (1) PT3463365T (enExample)
RU (1) RU2760681C2 (enExample)
SG (1) SG11201810323RA (enExample)
SI (1) SI3463365T1 (enExample)
WO (1) WO2017203270A1 (enExample)
ZA (1) ZA201807851B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
EP4142715A4 (en) * 2020-04-26 2024-05-15 Apollomics Inc. NEW PHARMACEUTICAL FORMULATION FOR C-MET INHIBITOR
CN113429396A (zh) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 一种五元杂芳环衍生物及其制备方法和用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051723A (enExample) 1962-04-27
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
US3252970A (en) 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (enExample) 1963-04-26
US3268558A (en) 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
GB1208014A (en) 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
BE790747A (fr) 1971-10-30 1973-02-15 Whitefin Holding Sa Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (fr) 1976-11-18 1977-03-16 Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent
US4316900A (en) 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
US6645976B1 (en) 1994-07-21 2003-11-11 Eli Lilly And Company Indolizine SPLA2inhibitors
KR19990008109A (ko) 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
EP0747756B1 (en) 1995-06-06 2000-05-24 Agfa-Gevaert N.V. Photographic materials
JPH09249669A (ja) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
CN100351230C (zh) 1998-06-03 2007-11-28 Gpinil控股公司 N-杂环化合物的羧酸和羧酸电子等排物
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
BR0010279A (pt) 1999-05-04 2002-05-14 Janssen Phamaceutica N V éteres antifúngicos
AU6438800A (en) 1999-07-30 2001-02-19 Norbert Heske Cannula system for introducing endoscopic tools in a human or animal body
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
DE60213802T2 (de) 2001-06-06 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Cak inhibitoren und deren verwendungen
KR100863113B1 (ko) 2001-06-20 2008-10-13 다이이찌 산쿄 가부시키가이샤 디아민 유도체
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
US20040162298A1 (en) 2002-02-23 2004-08-19 Hsu-Tso Ho Method of treating HIV infection by preventing interaction of CD4 and gp120
WO2004022100A1 (en) 2002-08-15 2004-03-18 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
US20050032871A1 (en) 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
JP2006520385A (ja) 2003-03-13 2006-09-07 シンタ ファーマスーティカルズ コーポレイション 縮合ピロール化合物
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06004438A (es) 2003-10-24 2006-06-20 Schering Ag Derivados de indolinona y su uso en el tratamiento de enfermedades como el cancer.
EP1753402B1 (en) 2004-05-28 2008-10-01 Pfizer Products Incorporated Pharmaceutical compositions with enhanced performance comprising a hpmca polymer
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
AU2006230364B2 (en) 2005-03-31 2012-09-13 Janssen Pharmaceutica N.V. Bicyclic pyrazole compounds as antibacterial agents
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006248812B2 (en) 2005-05-18 2012-02-16 F2G Ltd Antifungal agents
JP2009501721A (ja) 2005-07-12 2009-01-22 アカディア ファーマシューティカルズ インコーポレイテッド レチノイン酸受容体における活性を伴う化合物
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007109605A2 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
JP5508859B2 (ja) 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
CN101260086B (zh) 2007-03-06 2011-08-10 中国科学院上海药物研究所 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途
GB0710121D0 (en) 2007-05-25 2007-07-04 F2G Ltd Antifungal agents
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
JP5657524B2 (ja) 2008-04-24 2015-01-21 エフツージー リミテッド ピロール抗真菌剤
GB0809773D0 (en) 2008-05-29 2008-07-09 F2G Ltd Antifungal combination therapy
US20100093872A1 (en) 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
KR20120005460A (ko) 2009-04-28 2012-01-16 베링거 인겔하임 인터내셔날 게엠베하 Pkc-세타 억제제를 사용하는 면역학적 장애의 생체외 치료
WO2011159626A1 (en) 2010-06-14 2011-12-22 Bend Research, Inc. Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012060448A1 (ja) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
CN102805733B (zh) 2011-06-01 2016-03-09 日东电工株式会社 颗粒制剂及其制造方法
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
US9320799B2 (en) 2012-04-11 2016-04-26 Dow Global Technologies Llc Esterified cellulose ethers having a specific substituent distribution
BR112015002055A2 (pt) 2012-08-24 2017-07-04 Dow Global Technologies Llc acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
EP2888289B1 (en) 2012-08-24 2019-08-07 Dow Global Technologies LLC Partially cross-linked esterified cellulose ethers
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
WO2015007759A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA2928772A1 (en) 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
PL3221308T3 (pl) * 2014-11-21 2019-03-29 F2G Limited Środki przeciwgrzybicze
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation

Also Published As

Publication number Publication date
PT3463365T (pt) 2021-09-28
US20190328737A1 (en) 2019-10-31
MA45126A (fr) 2021-04-14
IL263167A (en) 2018-12-31
EP3463365A1 (en) 2019-04-10
RU2018142381A3 (enExample) 2020-09-30
HRP20211795T1 (hr) 2022-03-18
US10973821B2 (en) 2021-04-13
PL3463365T3 (pl) 2022-01-10
MY197663A (en) 2023-06-30
JP2019516765A (ja) 2019-06-20
HUE056129T2 (hu) 2022-01-28
CN109982704B (zh) 2023-10-24
AU2017270942A1 (en) 2018-12-06
JP7141108B2 (ja) 2022-09-22
LT3463365T (lt) 2021-11-10
BR112018074162A2 (pt) 2019-03-06
CA3024771A1 (en) 2017-11-30
GB201609222D0 (en) 2016-07-06
RU2018142381A (ru) 2020-06-25
CY1124733T1 (el) 2022-07-22
AU2017270942B2 (en) 2022-07-21
NZ748394A (en) 2024-11-29
KR102464150B1 (ko) 2022-11-07
CN109982704A (zh) 2019-07-05
SG11201810323RA (en) 2018-12-28
KR20190013865A (ko) 2019-02-11
MX2018014232A (es) 2019-03-28
SI3463365T1 (sl) 2022-01-31
RU2760681C2 (ru) 2021-11-29
DK3463365T3 (da) 2021-09-20
MX382199B (es) 2025-03-13
ZA201807851B (en) 2022-04-28
EP3463365B1 (en) 2021-08-25
ES2888951T3 (es) 2022-01-10
WO2017203270A1 (en) 2017-11-30
US20210186967A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
EP1982702B1 (en) Sirolimus formulation
JP5369332B2 (ja) 安定性を有するドセタキセル含有医薬組成物、及びその製造方法
CN101883765B (zh) 杂环化合物的无定形物、含有该无定形物的固体分散体、药剂及其制备方法
US20210186967A1 (en) Pharmaceutical formulation
JP2025134801A (ja) オラパリブの溶解度及び生体利用効率が改善された組成物
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
JP2012512840A (ja) ラサギリン成分を含有する固体組成物
JP2004534812A (ja) 薬物および中性ポリマーの分散物の医薬組成物
CN108938583A (zh) 包含无定形达格列净的制剂
CN101795673A (zh) 增强的拉莫三嗪制剂
CN102647978A (zh) 包含溶解性差的活性成分和高支化聚合物的药物组合物
CN101454003B (zh) 包含3-[5-[4-(环戊氧基)-2-羟基苯甲酰基]-2-[(3-羟基-1,2-苯并异噁唑-6-基)甲氧基]苯基]丙酸或其盐的口服组合物
EP3824888A1 (en) Orally administered pharmaceutical composition comprising fab i inhibitors and method for preparing same
JP2010511674A (ja) 抗hiv化合物の臭化水素酸塩
KR101331723B1 (ko) Hcv 중합효소 억제제 전구약물을 포함하는 약학 조성물
US10688090B2 (en) Vilazodone inclusion complexes, compositions and preparation thereof
ES2372983T3 (es) Proceso para preparar formulaciones secadas por aspersión de tmc125.
KR101151890B1 (ko) 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
WO2020111089A1 (ja) 医薬組成物
EP2925320B1 (en) Novel method for improving the bioavailability of low aqueous solubility drugs
KR20010041460A (ko) 지질 저하제 및 중합체로 피복된 핵을 갖는 펠릿
WO2014055397A1 (en) Tablet containing composite with cyclodextrin
BR112018074162B1 (pt) Método para produzir uma composição farmacêutica
US20210205301A1 (en) Vilazodone inclusion complexes, compositions and preparation thereof
WO2026019402A1 (en) A pharmaceutical composition comprising nanosuspension of canagliflozin